Ependymoma

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Rare CNS Tumors Outcomes &Risk

AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors

Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Selumetinib for NF2-Related Schwannomatosis

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Social Determinants of Health in Glioblastoma Population

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Methionine PET/CT Studies In Patients With Cancer

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)